As participants descended on San Diego for the American Society of Hematology (ASH) annual meeting, Fate Therapeutics Inc. prefaced its presentations with the disclosure that the FDA authorized its IND for FT-500, a universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. FT-500 is expected to be the first iPSC-derived cell product to move into the clinic in the U.S., and prospects for manufacturing from a single master pluripotent cell line "could revolutionize cell therapy," wrote Piper Jaffray's Edward Tenthoff in a hot comment.